6533b833fe1ef96bd129c0f9
RESEARCH PRODUCT
S2k Guidelines for Cutaneous Basal Cell Carcinoma - Part 2: Treatment, Prevention and Follow-up
Hans-peter HowaldtMarkus MeissnerBerenice M. LangMax SchlaakChristoph LöserMichael WeichenthalMichael P. SchönMichael Max SachseMarkus FollmannStephan GrabbeAndreas BlumJulia WelzelVinodh KakkasseryThomas DirschkaRoland KaufmannMichael TronnierJorge FrankG. Felix BrölschSusanne WiegandBernhard FrerichBernhard KlumppKlaus FritzAndrea BauerLudwig M. HeindlAlbrecht Krause-bergmannPanagiotis BalermpasStephan IhrlerLutz TischendorfAxel HauschildDirk Vordermarksubject
medicine.medical_specialtybusiness.industryIncidence (epidemiology)MEDLINEDermatologyDiseasemedicine.disease3. Good health030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinemedicineCarcinomaProfessional associationBasal cell carcinomaDisease management (health)Intensive care medicineRisk assessmentbusinessdescription
Basal cell carcinoma (BCC) is the most common malignant tumor among fair-skinned individuals, and its incidence had been steadily rising in the past decades. In order to maintain the highest quality of patient care possible, the German S2k guidelines were updated following a systematic literature search and with the participation of all professional societies and associations involved in the management of the disease. Part 2 addresses issues such as proper risk stratification, the various therapeutic approaches, and prevention as well as follow-up of patients with basal cell carcinoma.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2019-02-01 | JDDG: Journal der Deutschen Dermatologischen Gesellschaft |